CHANDAN HEALTHCARE LIMITED
Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021
CIN: L85110UP2003PLC193493
TEL NO.: -8069366666 **Email:** secretarial@chandan.co.in
www.chandandiagnostic.com

Date: 06-08-2026

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East), Mumbai – 400051

SYMBOL: CHANDAN
ISIN: INE0B2N01016

Subject: Outcome of the Board Meeting held on August 6, 2026

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Chandan Healthcare Limited ("Company"), at its meeting held today, i.e., August 6, 2026, inter alia, considered and approved the following:

Proposed disinvestment of entire shareholding in Chandan Pharmacy Limited

The Board has considered and approved, subject to the approval of the Members of the Company by way of a Special Resolution and such other approvals, consents and permissions as may be necessary, the proposed sale, transfer and disposal of the Company's entire shareholding in Chandan Pharmacy Limited, comprising 1,72,992 equity shares of face value of Rs.10/- each, representing approximately 53.56% of the paid-up equity share capital of Chandan Pharmacy Limited, to Chandan Hospital Limited.

The aggregate principal consideration for the proposed transaction is Rs.16,77,10,554.24 (Rupees Sixteen Crore Seventy-Seven Lakh Ten Thousand Five Hundred Fifty-Four and Twenty-Four Paise only), calculated at the independently determined fair value of Rs.969.47 per equity share, together with interest at the rate of 10% per annum on the actual outstanding/deferred principal consideration from time to time.

The principal consideration is proposed to be received as follows:

Payment Date (on or before)	% of Principal Consideration	Amount
September 1, 2026	25%	Rs.4,19,27,638.56
March 1, 2027	25%	Rs.4,19,27,638.56
September 1, 2027	50%	Rs.8,38,55,277.12
Total	100%	Rs.16,77,10,554.24

Interest at the rate of 10% per annum shall accrue on the actual outstanding principal consideration from time to time from September 1, 2026 until actual payment of the respective outstanding amount by Chandan Hospital Limited.

Upon completion of the proposed transfer, the Company's shareholding in Chandan Pharmacy Limited shall reduce from approximately 53.56% to Nil, and consequently Chandan Pharmacy Limited shall cease to be a subsidiary of the Company.

The Board has also approved in principle the draft Share Purchase Agreement proposed to be entered into with Chandan Hospital Limited, subject to approval of the Members and such modifications as may be necessary or appropriate for giving effect to the proposed transaction.

Considering that Chandan Pharmacy Limited is a material subsidiary of the Company, the Board has decided, as a measure of good corporate governance and consistent with the governance standards contemplated under Regulation 24(5) of the SEBI Listing Regulations, to place the proposed disinvestment before the Members of the Company for their approval by way of a Special Resolution.

The Board Meeting commenced at 02.00 P.M. and concluded at 04.15 P.M.

Yours sincerely,
For Chandan Healthcare Limited

RAJEEV NAIN Digitally signed by RAJEEV NAIN Date: 2026.08.06 16:21:52 +05'30'

Rajeev Kumar Nain
Company Secretary & Compliance Officer

Enclosure: As above

ANNEXURE-A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the applicable SEBI Master Circular

Details relating to the proposed sale/disposal of the entire shareholding held by Chandan Healthcare Limited in Chandan Pharmacy Limited

S. No.	Particulars	Details
1.	**The amount and percentage of turnover or revenue or income and net worth contributed by Chandan Pharmacy Limited during the last financial year**	Turnover/Revenue: Chandan Pharmacy Limited recorded turnover/revenue of Rs.120.22 crore for the financial year ended March 31, 2026, representing approximately 42.94% of the consolidated turnover/revenue of Chandan Healthcare Limited and its subsidiaries of approximately Rs.280 crore. Net Worth: The net worth of Chandan Pharmacy Limited as at March 31, 2026 was Rs.1,126.70 lakh (Rs.11.27 crore), representing approximately 6.63% of the consolidated net worth of Chandan Healthcare Limited and its subsidiaries of Rs.16,988.25 lakh (Rs.169.88 crore) as at March 31, 2026.
2.	**Date on which the agreement for sale has been entered into**	The Board of Directors has approved the proposed transaction and the draft Share Purchase Agreement ("SPA") in principle at its meeting held on August 6, 2026. The definitive SPA is proposed to be executed after receipt of the requisite approval of the Members of the Company.
3.	**Expected date of completion of sale/disposal**	On or about September 1, 2026, subject to receipt of requisite approvals and completion of applicable corporate, regulatory and depository formalities.
4.	**Consideration received from such sale/disposal**	The aggregate principal consideration for the proposed sale of 1,72,992 equity shares, representing approximately 53.56% of the paid-up equity share capital of Chandan Pharmacy Limited, is Rs.16,77,10,554.24, calculated at the independently determined fair value of Rs.969.47 per equity share, together with interest at 10% per annum on the actual outstanding/deferred principal consideration from time to time. As the transaction is yet to be completed, no sale consideration has been received as on the date of this disclosure.
5.	**Brief details of buyer and whether the buyer belongs to the promoter/promoter group/group companies; if yes, details thereof**	The proposed purchaser is Chandan Hospital Limited, an unlisted public company forming part of the Chandan Group. Chandan Hospital Limited is a related party/group company of Chandan Healthcare Limited.
6.	**Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"**	Yes. The proposed transaction is a Related Party Transaction. The consideration has been determined based on an independent valuation undertaken by a Registered Valuer, who has determined the fair value of the equity shares of Chandan Pharmacy Limited at Rs.969.47 per equity share. The transaction is

S. No.	Particulars	Details
		proposed to be undertaken on an arm's-length basis, subject to the terms and conditions contained in the definitive transaction documents.
7.	**Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details thereof including compliance with Regulation 37A of the SEBI Listing Regulations**	The proposed transaction involves the sale of equity shares held by the Company in its subsidiary and does not involve sale, lease or disposal of an undertaking of the Company. Accordingly, Regulation 37A of the SEBI Listing Regulations is not applicable to the proposed transaction.
8.	**In case of a slump sale, indicative disclosures provided for amalgamation/merger**	Not Applicable, as the proposed transaction is a sale/transfer of equity shares and is not a slump sale.
9.	**Shareholding proposed to be disposed of**	1,72,992 equity shares of face value of Rs.10/- each, representing approximately 53.56% of the paid-up equity share capital of Chandan Pharmacy Limited, being the entire shareholding held by Chandan Healthcare Limited in Chandan Pharmacy Limited.
10.	**Payment terms**	25% – Rs.4,19,27,638.56 payable on or before September 1, 2026, 25% – Rs.4,19,27,638.56 payable on or before March 1, 2027; and 50% – Rs.8,38,55,277.12 payable on or before September 1, 2027.
11.	**Interest on deferred consideration**	Interest at 10% per annum shall accrue on the actual outstanding principal consideration from time to time from September 1, 2026 until actual payment of the respective outstanding amount by Chandan Hospital Limited.
12.	**Effect of the proposed transaction**	Upon completion of the proposed transfer, Chandan Healthcare Limited's shareholding in Chandan Pharmacy Limited shall reduce from approximately 53.56% to Nil, and consequently Chandan Pharmacy Limited shall cease to be a subsidiary of Chandan Healthcare Limited.
13.	**Approval of Members**	The proposed transaction is subject to approval of the Members of Chandan Healthcare Limited by way of a Special Resolution. The Extraordinary General Meeting of the Company is proposed to be held on Saturday, August 29, 2026 at 4:00 P.M. (IST) through VC/OAVM.